Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

Frontiers in Nuclear Medicine

Nuclear Medicine

Siraj Yusuf¹  Carla Abreu²  Lily Carnegie-Peake²  Lenka Vávrová²  Paul Gape²  Jan Taprogge²  Iain Murray²  Dominic Rushforth²  Jonathan Gear²  Glenn Flux²  Kee H. Wong³  Kate Newbold³ 

[1] Department of Nuclear Medicine and PET/CT, Royal Marsden NHSFT, Sutton, United Kingdom;Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom;Radioisotope Physics, Institute of Cancer Research, London, United Kingdom;Thyroid Unit, Royal Marsden NHSFT, Sutton, United Kingdom;

关键词: multi-centre trial;    dosimetry;    radioiodine;    differentiated thyroid cancer;    residual thyroid tissue;   

DOI  :  10.3389/fnume.2023.964478

 received in 2022-06-08, accepted in 2023-04-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionThe optimal strategy for differentiated thyroid cancer (DTC) patients treated with radioiodine (RAI) following thyroidectomy remains controversial. Multi-centre clinical studies are essential to identify strategies to improve patient outcomes while minimising treatment-induced toxicity.MethodsThe INSPIRE clinical trial (ClinicalTrials.gov Identifier: NCT04391244) aims to investigate patient-specific dosimetry for DTC patients and to determine the range of absorbed doses delivered to target and non-target tissues and their relationship with treatment outcome and toxicity.ResultsWe report here initial results of the first 30 patients enrolled onto the INSPIRE trial. A large range of absorbed doses are observed for both thyroid remnants and salivary glands, with median values of 4.8 Gy (Range 0.2 – 242 Gy) and 0.3 Gy (Range 0.1 to 1.7 Gy), respectively.DiscussionThe preliminary study results are encouraging and could help to improve our understanding of absorbed doses to thyroid remnants and normal organs following RAI therapy. Such knowledge could potentially enable patient-specific treatment planning with improved clinical outcomes and quality-of-life of patients.

【 授权许可】

Unknown   
© 2023 Taprogge, Abreu, Vávrová, Carnegie-Peake, Rushforth, Gape, Gear, Murray, Wong, Newbold, Yusuf and Flux.